Biogen Inc. (BIIB) vs Medline Inc. (MDLN)

A side-by-side comparison of Biogen Inc. and Medline Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total returnBIIB vs MDLN

growth of $100 · dividends reinvested · last 1y
BIIB +16.1%MDLN -3.2%BIIB compounded faster
8090100110120Start $1002026$116$97
BIIB MDLN

BIIB vs MDLN: by the numbers

  • MDLN is the larger company ($34.26B vs $30.36B market cap).
  • BIIB trades at the lower trailing earnings multiple (21.43 vs 32.81 P/E), one valuation lens rather than an overall verdict.
  • BIIB converts more revenue to profit (13.92% vs 3.31% net margin).

Metrics side by side

Valuation

MetricBIIBMDLN
P/E ratio21.4332.81
Forward P/E15.7126.21
P/S ratio3.011.12
P/B ratio1.592.91
EV / EBITDA13.5314.47
FCF yield8.83%4.66%

Profitability

MetricBIIBMDLN
Gross margin69.77%24.04%
Operating margin15.65%7.04%
Net margin13.92%3.31%
ROE7.36%8.55%
ROIC6.62%5.69%

Growth (annualized)

MetricBIIBMDLN
Revenue CAGR (5Y)-4.80%N/A
EPS CAGR (5Y)-18.67%N/A
FCF CAGR (5Y)-3.59%N/A
Total return CAGR (5Y)-9.48%N/A

Frequently asked

Which has the lower trailing P/E, BIIB or MDLN?
BIIB has the lower trailing P/E: BIIB trades at 21.43 and MDLN at 32.81. P/E is one valuation measure and does not by itself establish which business is cheaper.
Is BIIB or MDLN more profitable?
BIIB runs the higher net margin — BIIB at 13.92% versus MDLN at 3.31%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.